Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?

Innovent has strengthened its pitch for the Chinese obesity market with fresh phase 2 data. The update shows giving mazdutide, a molecule from Eli Lilly’s deep bench of obesity assets, at a higher dose dialed up the placebo-adjusted weight loss to 15.4% after 24 weeks.